valine has been researched along with thromboplastin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertina, RM; Cupers, R; Mannucci, PM; Poort, SR; Reinalda-Poot, HH; Reitsma, PH; van der Linden, IK | 1 |
| Breu, V; Dechend, R; Fiebeler, A; Ganten, D; Gulba, D; Haller, H; Luft, FC; Luther, T; Mackman, N; Mervaala, EM; Müller, DN; Park, JK; Schmidt, F; Schneider, W; Theuer, J | 1 |
| Bernardi, F; Camire, RM; High, KA; Marchetti, G; Pinotti, M; Pollak, ES; Tidd, T; Toso, R | 1 |
| Beck, DO; Bukys, MA; Kalafatis, M; Singh, LS | 1 |
| Osório e Castro, VR; Vernon, LP | 1 |
| Nielsen, PF; Olsen, OH; Persson, E | 1 |
| Chen, LF; Ke, YN; Li, N; Zhu, WL | 1 |
| Chang, KC; Ha, YM; Kang, YJ; Kim, HJ; Park, EJ; Park, SW | 1 |
8 other study(ies) available for valine and thromboplastin
| Article | Year |
|---|---|
Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
Topics: Amino Acid Sequence; Antibodies, Monoclonal; Arginine; Binding Sites; Binding, Competitive; Chymotrypsin; DNA Restriction Enzymes; Factor IX; Factor VIIa; Factor X; Factor XIa; Hemophilia A; Humans; Molecular Sequence Data; Molecular Weight; Mutation; Protein Conformation; Prothrombin Time; Thromboplastin; Valine | 1990 |
Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Blood Coagulation Factors; Blood Pressure; Cell Line; CHO Cells; Coronary Disease; Coronary Vessels; Cricetinae; Extracellular Matrix Proteins; Heart Ventricles; Humans; Inflammation; Integrin alpha4beta1; Integrins; NF-kappa B; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Lymphocyte Homing; RNA, Messenger; Tetrazoles; Thromboplastin; Transcription Factor AP-1; Valine; Valsartan; Vascular Resistance | 2000 |
Factor VII mutant V154G models a zymogen-like form of factor VIIa.
Topics: Alanine; Amino Acid Chloromethyl Ketones; Binding Sites; Enzyme Precursors; Factor VII; Factor VIIa; Humans; Isoleucine; Point Mutation; Protein Conformation; Serine Proteinase Inhibitors; Thromboplastin; Valine | 2003 |
Amino acids Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for expression of cofactor activity.
Topics: Amino Acids; Animals; Anisotropy; Binding Sites; Blotting, Western; COS Cells; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Factor Va; Factor Xa; Glutamic Acid; Humans; Kinetics; Mutagenesis, Site-Directed; Mutation; Peptides; Protein Binding; Prothrombin; Recombinant Proteins; Spectrometry, Fluorescence; Thrombin; Thromboplastin; Time Factors; Transfection; Tyrosine; Valine | 2003 |
Stimulation of prothrombinase activity by the nonapeptide Thr-Trp-Ala-Arg-Asn-Ser-Tyr-Asn-Val, a segment of a plant thionin.
Topics: Calcium; Cell Membrane; Cysteine; Cystine; Dose-Response Relationship, Drug; Erythrocyte Membrane; Factor Va; Factor Xa; Humans; Nuts; Peptides; Plant Proteins; Pyrularia; Spectrophotometry; Temperature; Thrombin; Thromboplastin; Time Factors; Valine | 2003 |
Prevention of beta strand movement into a zymogen-like position does not confer higher activity to coagulation factor VIIa.
Topics: Allosteric Site; Amino Acid Sequence; Animals; Cell Line; Chromogenic Compounds; Cricetinae; Cysteine; Enzyme Activation; Enzyme Precursors; Factor VIIa; Genetic Variation; Humans; Hydrolysis; Molecular Sequence Data; Mutagenesis, Site-Directed; Protein Structure, Secondary; Substrate Specificity; Thermodynamics; Thromboplastin; Transfection; Valine | 2004 |
[Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor].
Topics: Animals; Captopril; Cells, Cultured; Endothelium, Vascular; Male; Proton-Translocating ATPases; Rabbits; RNA, Messenger; Tetrazoles; Thromboplastin; Valine; Valsartan | 2006 |
Valsartan independent of AT₁ receptor inhibits tissue factor, TLR-2 and -4 expression by regulation of Egr-1 through activation of AMPK in diabetic conditions.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Cells, Cultured; Chromatin Immunoprecipitation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Early Growth Response Protein 1; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glucose Tolerance Test; Humans; Male; Mice; Mice, Inbred C57BL; Monocytes; Receptor, Angiotensin, Type 1; RNA, Small Interfering; Tetrazoles; Thromboplastin; Toll-Like Receptor 2; Toll-Like Receptor 4; Valine; Valsartan | 2014 |